Two-Dimensional Protein Analysis of Primary Rat and Human Cortical Cultures: Alteration of Total Protein Expression Profiles after Treatment with Fibrillar Aβ

2000 ◽  
Vol 28 (1) ◽  
pp. A37-A37
Author(s):  
R Williamson ◽  
T.E.O. Schubert ◽  
I.P. Everall ◽  
B.H. Anderton
Keyword(s):  
Protein Expression ◽  
Total Protein ◽  
Expression Profiles ◽  
Protein Analysis ◽  
Two Dimensional ◽  
Cortical Cultures ◽  
Protein Expression Profiles ◽  
Total Protein Expression

scholarly journals The Hidden Story on Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma – Association with Clinical Outcome and Tumor Phenotypes

2019 ◽  
Author(s):  
Lazaro Hiram Betancourt ◽  
A. Marcell Szasz ◽  
Magdalena Kuras ◽  
Jimmy Rodriguez Murillo ◽  
Yutaka Sugihara ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Protein Expression ◽  
Human Cancer ◽  
Expression Profiles ◽  
Drug Efficacy ◽  
Protein Analysis ◽  
Braf V600e ◽  
Current Recommendation ◽  
Cancer Types ◽  
Protein Expression Profiles

In comparison to other human cancer types, malignant melanoma exhibits the greatest amount of heterogeneity. After DNA-based detection of the BRAF V600E mutation in melanoma patients, targeted inhibitor treatment is the current recommendation. This approach, however, does not take the abundance of the therapeutic target, i.e., the B-raf V600E protein, into consideration. As shown by immunohistochemistry, the protein expression profiles of metastatic melanomas do clearly reveal the existence of inter- and intra-tumor variability. Nevertheless, the technique is only semi-quantitative. To quantitate the mutant protein there is a fundamental need for more precise techniques that are aimed at defining the currently non-existent link between the levels of the target protein and subsequent drug efficacy. Using cutting-edge mass spectrometry combined with DNA and mRNA sequencing, the mutated B-raf protein within metastatic tumors was quantitated for the first time. B-raf V600E protein analysis revealed a subjacent layer of heterogeneity for mutation-positive metastatic melanomas. These were characterized into two distinct groups with different tumor morphologies, protein profiles and patient clinical outcomes. This study provides evidence that a higher level of expression for the mutated protein is associated with a more aggressive tumor progression. Our study design that is comprised of surgical isolation of tumors, histopathological characterization, tissue biobanking, and protein analysis may enable the eventual delineation of patient responders/non-responders and the subsequent therapy of malignant melanoma.

scholarly journals The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma—Association with Clinical Outcome and Tumor Phenotypes

Cancers ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 1981 ◽  
Author(s):  
Lazaro Hiram Betancourt ◽  
A. Marcell Szasz ◽  
Magdalena Kuras ◽  
Jimmy Rodriguez Murillo ◽  
Yutaka Sugihara ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Protein Expression ◽  
Human Cancer ◽  
Expression Profiles ◽  
Drug Efficacy ◽  
Protein Analysis ◽  
Braf V600e ◽  
Current Recommendation ◽  
Cancer Types ◽  
Protein Expression Profiles

In comparison to other human cancer types, malignant melanoma exhibits the greatest amount of heterogeneity. After DNA-based detection of the BRAF V600E mutation in melanoma patients, targeted inhibitor treatment is the current recommendation. This approach, however, does not take the abundance of the therapeutic target, i.e., the B-raf V600E protein, into consideration. As shown by immunohistochemistry, the protein expression profiles of metastatic melanomas clearly reveal the existence of inter- and intra-tumor variability. Nevertheless, the technique is only semi-quantitative. To quantitate the mutant protein there is a fundamental need for more precise techniques that are aimed at defining the currently non-existent link between the levels of the target protein and subsequent drug efficacy. Using cutting-edge mass spectrometry combined with DNA and mRNA sequencing, the mutated B-raf protein within metastatic tumors was quantitated for the first time. B-raf V600E protein analysis revealed a subjacent layer of heterogeneity for mutation-positive metastatic melanomas. These were characterized into two distinct groups with different tumor morphologies, protein profiles and patient clinical outcomes. This study provides evidence that a higher level of expression in the mutated protein is associated with a more aggressive tumor progression. Our study design, comprised of surgical isolation of tumors, histopathological characterization, tissue biobanking, and protein analysis, may enable the eventual delineation of patient responders/non-responders and subsequent therapy for malignant melanoma.

P-652 Protein expression profiles in non-small cell lung cancer. A tissue microarray-based study of 142 cases

Lung Cancer ◽  
2005 ◽  
Vol 49 ◽  
pp. S290 ◽  
Author(s):  
E. Conde ◽  
R. García Luján ◽  
A. López Encuentra ◽  
L. Sánchez ◽  
M. Sánchez-Céspedes ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Protein Expression ◽  
Small Cell Lung Cancer ◽  
Tissue Microarray ◽  
Cell Lung Cancer ◽  
Expression Profiles ◽  
Small Cell ◽  
Small Cell Lung ◽  
Protein Expression Profiles

scholarly journals Brain death induces the alteration of liver protein expression profiles in rabbits

2014 ◽  
Vol 34 (2) ◽  
pp. 578-584 ◽  
Author(s):  
BING DU ◽  
LING LI ◽  
ZHIBIAO ZHONG ◽  
XIAOLI FAN ◽  
BINGBING QIAO ◽  
...  
Keyword(s):  
Protein Expression ◽  
Brain Death ◽  
Expression Profiles ◽  
Liver Protein ◽  
Protein Expression Profiles
Sign in / Sign up

Export Citation Format

Share Document